Table 1 Demographics, previous and concomitant therapies, and disease status at baseline.

SDAI, simplified disease activity index; no., number; BMI, body mass index; MTX, methotrexate; ACPA, anticitrullinated protein antibody; IgM-RF, immunoglobulin M rheumatoid factor; DAS28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire.

Patients (n = 193)
Demographics
Age, means ± SD (years)54 ± 11
Female, no. (%)148 (77)
BMI, means ± SD25.7 ± 5.1
DMARD therapy
Previous DMARDs, median (IQR)3 (2–4)
MTX use, no. (%)149 (77)
MTX dose, median (IQR) (mg/week)25 (15–25)
Prednisone use, no. (%)60 (31)
Prednisone dose, median (IQR) (mg/day)7 (5–10)
Disease status
Disease duration, median (IQR) (years)8 (3–17)
ACPA positive, no. (%)138 (72)
IgM-RF positive, no. (%)135 (70)
Erosive, no. (%)143 (74)
DAS28, means ± SD5.0 ± 1.3
SDAI, means ± SD21 (14–27)
ESR, medians (IQR) (mm/hour)21 (9–42)
CRP, median (IQR) (mg/liter)11 (4–23)
HAQ, median (IQR)1.1 (0.8–1.6)